糖尿病黄斑水肿中硬性渗出的研究进展  

The research advancement of macular hard exudates in diabetic macular edema

作　　者：朱莹莹 王海燕 张敬法 Zhu Yingying;Wang Hai-yan;Zhang Jingfa(Department of Ophthalmology,the First Affiliated Hospital of Wannan Medical College,Wuhu 241000,China;Xi’an People’s Hospital(Xi’an Fourth Hospital),Xi’an 710004,China;Department of Ophthalmology,Shanghai General Hospital(Shanghai First People’s Hospital),Shanghai Jiao Tong University,Shanghai 200080,China)

机构地区：[1]皖南医学院第一附属医院眼科,芜湖241000 [2]西安市人民医院西安市第四医院,710004 [3]上海市第一人民医院眼科,200080

出　　处：《临床眼科杂志》2024年第3期274-278,共5页Journal of Clinical Ophthalmology

基　　金：国家自然科学基金面上项目(82171062);国家自然科学基金联合基金项目(U2267220)。

摘　　要：糖尿病视网膜病变(DR)患者黄斑区的硬性渗出(HEs)是导致患者视力预后差的重要因素之一。近年来,眼内注射抗血管内皮生长因子(Anti-VEGF)药物可有效治疗糖尿病黄斑水肿(DME)。然而随着水肿的消退,黄斑区的HEs却呈现出动态变化的过程、甚至在中心凹处积聚。随着视网膜成像技术的不断发展和更新,我们能更直观地观察HEs,并对HEs的来源、分布和消退有着较为深刻的认识和理解。本文主要阐述了DME中HEs的一般形态特征、来源及消退等特征,并阐述了当前治疗措施对HEs的消退作用,以期为伴HEs的DME患者在早期诊断、治疗和预后等方面提供借鉴和依据,为研发消退HEs药物或其他治疗手段提供基础。The macular hard exudates(HEs)are one of the key factors resulting in poor vision prognosis in pa⁃tients with diabetic retinopathy(DR).Recently,intraocular injection of anti-vascular endothelial growth factor(anti-VEGF)remains an effective treatment for diabetic macular edema(DME).However,HEs in the macular region showed a dynamic change,and even accumulated in the fovea as the edema resolved.With the development and update of retinal im⁃aging technology,we can observe HEs more intuitively,which deepens our understanding of their origin,distribution and regression.This review mainly describes the general morphological characteristics,the origin and regression of HEs in DME,and also describes the current treatments to eliminate HEs,so as to provide the reference and basis for the early di⁃agnosis,treatment and prognosis in DME patients with HEs,and also to provide the basis for the development of drugs or other treatments for HEs regression.

关 键 词：硬性渗出 糖尿病视网膜病变 糖尿病黄斑水肿 相干光层析成像术 

分 类 号：R587.2[医药卫生—内分泌] R774.1[医药卫生—内科学]